---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-121685"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-11-03T13:20:04+00:00"
generated_at: "2026-11-03T13:25:48.373535+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Acura Pharmaceuticals borrows $141,607 from AD Pharma; note balance hits $11.44M with going-concern warning

## Summary
- Two new loans of $41,607 (Oct 19, 2026) and $100,000 (Oct 30, 2026) from Abuse Deterrent Pharma bring the secured note principal to $11,435,886.
- Accrued interest is approximately $1,416,000 as of October 31, 2026; the note bears 5.25% interest, rising to 7.5% on overdue amounts.
- Acura says without additional financing by late-November 2026 it must furlough or lay off employees, terminate operations, or seek bankruptcy protection.
- AD Pharma agreement requires FDA acceptance of an NDA for LTX-03 by December 31, 2026, and payoff of the secured note by the same date.
- Loan #66 of $100,000 on October 2, 2026 preceded the two disclosed loans; total aggregated principal rose from $2,319,279 in November 2022.

## SEC filing metadata
- accession: 0001104659-26-121685
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-11-03T13:20:04+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926121685/0001104659-26-121685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926121685/tm2628790d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-121685
- JSON: https://secwatch.observer/filing/0001104659-26-121685.json
- Plain text: https://secwatch.observer/filing/0001104659-26-121685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.